UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

For the month of ~~February~~March 2026

Commission File Number: ~~001~~002-~~42484~~023311

ASCENTAGE PHARMA GROUP INTERNATIONAL

(Translation of Registrant’s name into English)

68 Xinqing Road

Suzhou Industrial Park

Suzhou, Jiangsu

China

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

~~EXPLANATORY~~ On March ~~NOTE~~11, 2026, Ascentage Pharma Group International (“Ascentage Pharma” or the “Company”) issued a press release entitled, “Ascentage Pharma To Report Full Year 2025 Unaudited Financial Results And Provide Business Updates On March 25, 2026”. A copy of the press release is furnished as Exhibit 99.1 to this Report.

On February 23, 2026, Ascentage Pharma Group International issued a press releases entitled “Ascentage Pharma to Participate in Three Upcoming Investor Conferences”. A copy of the press release is furnished as Exhibit 99.1.

INDEX TO EXHIBITS

Exhibit
Exhibit Number		Exhibit Title
Number		Exhibit Title
99.1		Press release dated March 11, 2026
99.1		Press Release dated February 23, 2026

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	ASCENTAGE PHARMA GROUP INTERNATIONAL
Date: February 23, 2026	/s/ Dajun Yang
Date: March 11, 2026	/s/ Dajun Yang
	Name:	Dajun Yang
	Name: Dajun Yang
	Title:	Chief Executive Officer
	Title: Chief Executive Officer

Filing Compare · ASCENTAGE PHARMA GROUP INTERNATIONAL